<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00946374</url>
  </required_header>
  <id_info>
    <org_study_id>L-149/2003</org_study_id>
    <secondary_id>BfArM: A-7140-00-37/4021157</secondary_id>
    <nct_id>NCT00946374</nct_id>
  </id_info>
  <brief_title>Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma</brief_title>
  <acronym>HD-MCL2003</acronym>
  <official_title>A Prospective Phase II Trial on R-CHOP Followed by High-dose BEAM and Autologous SCT and HLA-identical Allogenic SCT After Dose-reduced Conditioning in Patients Age &lt; 55 Years With Primary Mantle-Cell-Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to improve the overall survival of Mantle-Cell-Lymphoma (MCL) by
      a new concept of treatment with primary curative intention consisting of six courses of
      immunochemotherapy followed by high-dose chemotherapy and autologous stem cell
      transplantation (SCT) and HLA-identical allogenic SCT after a dose-reduced conditioning
      regimen of total body irradiation (TBI) with 2 Gy and Fludarabine in younger patients with
      primary Mantle-Cell-Lymphoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      With a median overall survival of approximately 3 years, MCL has the poorest prognosis of all
      NHL entities. No potentially curative therapy has been established yet as even more intensive
      therapies including high-dose chemotherapy plus autologous SCT show only moderate improvement
      of the prognosis of MCL. Allogenic SCT seems to have an immunological mechanism of action in
      NHL, which is commonly known as Graft-versus-Lymphoma effect. This trial´s purpose is to
      improve the overall survival in patients younger than 55 years with primary MCL by
      sequentially combining autologous SCT and allogenic SCT after the application of 6 courses of
      immunochemotherapy and high-dose chemotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2004</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: ORR, OS, EFS</measure>
    <time_frame>during treatment and on day 720 after allogenic SCT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity according to WHO-Grading</measure>
    <time_frame>During treatment and until follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GvL-effect after allogenic SCT</measure>
    <time_frame>Allogenic SCT until day 720 after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of OS between patients completing the protocol and patients not receiving allogenic SCT</measure>
    <time_frame>First diagnosis of MCL until day 720 after transplantation</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Mantle-Cell Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Immunochemotherapy</intervention_name>
    <description>R-CHOP: Rituximab 375 mg/m²,intravenous ( iv ), day 0 ; Cyclophosphamide 750 mg/m²,iv, day1; Vincristine 1,4 mg/m² but at the maximum 2 mg,iv,d1; Doxorubicin 50 mg/m², iv, d1; Prednisone 100 mg, peroral ( po ), day 1 to day 5</description>
    <other_name>R-CHOP</other_name>
    <other_name>CHOP</other_name>
    <other_name>MabThera®</other_name>
    <other_name>Endoxan®</other_name>
    <other_name>Cytoxan®</other_name>
    <other_name>Neosar®</other_name>
    <other_name>Procytox®</other_name>
    <other_name>Revimmune®</other_name>
    <other_name>Oncovin®</other_name>
    <other_name>Adriamycin®</other_name>
    <other_name>Decortin®</other_name>
    <other_name>Corticosteroid</other_name>
    <other_name>Steroid</other_name>
    <other_name>Cellcristin®</other_name>
    <other_name>CAELYX®</other_name>
    <other_name>Adriblastin®</other_name>
    <other_name>Doxo-Cell®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>High-dose BEAM plus autologous SCT</intervention_name>
    <description>High-dose BEAM: Carmustine 300mg/m², iv, day -7; Cytarabine 2 x 200 mg/m², iv, day -6 to day -3; Etoposide 2 x 100 mg/m², iv, day -6 to day -3; Melphalan 140 mg/m², iv, day -2 followed by Autologous stem cell transplantation ( &gt; 2,5 x 10e6 CD34 positive autologous stem cells, iv, day 0</description>
    <other_name>BEAM</other_name>
    <other_name>High-dose BEAM</other_name>
    <other_name>ABSCT</other_name>
    <other_name>ASCT</other_name>
    <other_name>BCNU</other_name>
    <other_name>Crmubris®</other_name>
    <other_name>ARA-C</other_name>
    <other_name>Eposin®</other_name>
    <other_name>Etopophos®</other_name>
    <other_name>ETO CELL®</other_name>
    <other_name>Vepesid®</other_name>
    <other_name>VP-16®</other_name>
    <other_name>Alkeran®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>HLA-identical allogenic SCT</intervention_name>
    <description>Fludarabine 30 mg/m², iv, day -4 to day -2; Cyclosporin A 2 x 3mg/kg, iv, day -1 to day 0 plus total body irradiation with 2 Gy, day 0 followed by allogenic stem cell transplantation immediately after Radiation.</description>
    <other_name>Sibling donor</other_name>
    <other_name>Unrelated donor</other_name>
    <other_name>HLA-identical</other_name>
    <other_name>Conditioning regimen</other_name>
    <other_name>Fludara®</other_name>
    <other_name>Sandimmune®</other_name>
    <other_name>Fludarabinphosphat</other_name>
    <other_name>Neoflubin®</other_name>
    <other_name>TBI</other_name>
    <other_name>Ciclral®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. First diagnosis of Mantle-Cell-Lymphoma without any previous therapies except for
             pre-phase treatment consisting of steroids

          2. Age 18 to 55 years

          3. Confirmed CD20-expression on lymphocytes

          4. Effective methods of contraception and negative pregnancy test

          5. Sufficient compliance

          6. Written patient´s informed consent

        Exclusion Criteria:

          1. Manifest cardiac insufficiency, not compensated

          2. Congestive Cardiomyopathy

          3. Chronic pulmonary disease including hypoxemia

          4. Severe hypertension, not condensable with drugs

          5. Severe diabetes mellitus not condensable with drugs

          6. Renal Insufficiency ( serum creatinin &gt; 2,0 mg/dl, other than Lymphoma related)

          7. Liver impairment ( Transaminases value more than 3 x upper normal value or Bilirubin &gt;
             2,0 mg/dl, other than Lymphoma related)

          8. HIV-Infection

          9. Active Hepatitis B-Infection if continuous virostatic treatment is not possible

         10. Active Hepatitis C-Infection

         11. Clinical signs of cerebrovascular insufficiency or cerebral damages

         12. Pregnancy, lactation or inadequate contraception in women of childbearing age

         13. Severe psychiatric disorders

         14. Transplantation in the past
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony D. Ho, Ph.D., Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director of Department</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Markus Munder, M. D.</last_name>
    <phone>0049 6221 56</phone>
    <phone_ext>32370</phone_ext>
    <email>markus.munder@med.uni-heidelberg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Munder, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.klinikum.uni-heidelberg.de</url>
    <description>Homepage University hospital Heidelberg, Germany</description>
  </link>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2009</study_first_submitted>
  <study_first_submitted_qc>July 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2009</study_first_posted>
  <last_update_submitted>July 24, 2009</last_update_submitted>
  <last_update_submitted_qc>July 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2009</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. med. A. D. Ho</name_title>
    <organization>University of Heidelberg</organization>
  </responsible_party>
  <keyword>Mantle-Cell-Lymphoma</keyword>
  <keyword>MCL</keyword>
  <keyword>Non Hodgkin´s Lymphoma</keyword>
  <keyword>NHL</keyword>
  <keyword>Immunochemotherapy</keyword>
  <keyword>R-CHOP</keyword>
  <keyword>CHOP</keyword>
  <keyword>High-dose chemotherapy</keyword>
  <keyword>BEAM</keyword>
  <keyword>HD-BEAM</keyword>
  <keyword>Autologous stem cell transplantation</keyword>
  <keyword>Reduced conditioning regimen</keyword>
  <keyword>Unrelated donor</keyword>
  <keyword>Sibling donor</keyword>
  <keyword>Total Body Irradiation</keyword>
  <keyword>TBI</keyword>
  <keyword>Allogenic stem cell transplantation</keyword>
  <keyword>ABSCT</keyword>
  <keyword>ASCT</keyword>
  <keyword>Fludarabine+TBI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

